Scott Galasinski

Scientific Advisory Board Member @Idefine-The Kleefstra Syndrome Foundation

Chicago, IL, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Aug 2023 — Present

Scientific Advisory Board Member @Idefine-The Kleefstra Syndrome Foundation

View department →

US

iDefine is committed to identifying life-changing treatments and cures for those with Kleefstra Syndrome (KS), a neurodevelopmental disorder caused by haploinsufficiency of the epigenetic regulator EHMT1 gene. idefine.org

EDUCATION

N/A

Northern Illinois University

M.S., B.S., Biology and Chemistry

N/A

Penn State University

Post Doctoral, HHMI Fellowship, Epigenetics

N/A

University of Colorado Boulder

Ph.D, Molecular, Cellular, and Developmental Biology; Dissertation in Biochemistry

SKILLS

BiomarkersAntibodiesCell BiologyGenomicsDrug DiscoverySignal TransductionHigh Throughput ScreeningMechanism of Action StudiesBiotechnologyProtein PurificationMolecular BiologyTarget IdentificationIn VitroCell CultureLc-MsLife SciencesLifesciencesAssay DevelopmentMass SpectrometryBiochemistryProtein ChemistryToxicologyLiquid Chromatography-Mass Spectrometry (Lc-Ms)

ABOUT SCOTT GALASINSKI

I am a scientific and strategic business executive with 20+ years of leadership experience in biopharma and animal health, specializing in translational research, business development, licensing, acquisitions, and portfolio strategy. My career spans senior roles at Elanco, AstraZeneca, Novartis, Ultragenyx, and AbbVie, where I have built high-performing teams, executed transformative partnerships, and advanced assets from discovery through late-stage development.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Scott Galasinski — Scientific Advisory Board Member at Idefine-The Kleefstra Syndrome Foundation in Chicago, IL, US | Unifers